Glenmark Pharmaceuticals Ratios

Glenmark Pharmaceuticals Ltd Ratios

The Glenmark Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Glenmark Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Glenmark Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) is currently trading at ₹2136.70, with a market capitalization of ₹603.26B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Glenmark Pharmaceuticals Ltd remains a key stock for fundamental analysis using Glenmark Pharmaceuticals Ltd Ratios.

Glenmark Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Glenmark Pharmaceuticals Ltd P/E ratio currently stands at 41.51, making it one of the most tracked metrics in Glenmark Pharmaceuticals Ltd Ratios.

Historically, the Glenmark Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 41.51
• 2023: 0
• 2022: 44.14
• 2021: 13.25
• 2020: 13.51

The rising Glenmark Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Glenmark Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 4.91.

Historical P/B trend:

• 2024: 4.91
• 2023: 3.44
• 2022: 1.38
• 2021: 1.37

Glenmark Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Glenmark Pharmaceuticals Ltd P/S ratio currently stands at 3.26, an important part of Glenmark Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.26
• 2023: 2.29
• 2022: 1.13
• 2021: 1.01

The rising Glenmark Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Glenmark Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Glenmark Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Glenmark Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 38.94
• 2021: 14.38
• 2020: 15.59

The declining Glenmark Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Glenmark Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Glenmark Pharmaceuticals Ltd EV currently stands at ₹442.22B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 442.22B
• 2023: 265.84B
• 2022: 169.25B
• 2021: 153.74B

Glenmark Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Glenmark Pharmaceuticals Ltd EV/EBITDA ratio is currently 18.56, a key metric in Glenmark Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 18.56
• 2023: 21.58
• 2022: 10.13
• 2021: 6.49

Stable Glenmark Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Glenmark Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Glenmark Pharmaceuticals Ltd D/E ratio is currently 0.28, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.28
• 2023: 0.16
• 2022: 0.49
• 2021: 0.44

Glenmark Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Glenmark Pharmaceuticals Ltd ROE currently stands at 12.54%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 12.54
• 2023: -21.93
• 2022: -1.83
• 2021: 11.66

Glenmark Pharmaceuticals Ltd maintains stable profitability levels.

Glenmark Pharmaceuticals Ltd Ratios Analysis Summary

The Glenmark Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Glenmark Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Glenmark Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.